Table 5 Top 10 cited documents of biosimilars research. Scopus 2004–2016
From: A bibliometric analysis of the global research on biosimilars
Rank | Title | Year | Journal name | Cited by | Type of document |
|---|---|---|---|---|---|
1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | 2014 | Annals of the Rheumatic Diseases | 962 | Article |
2 | 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours | 2011 | European Journal of Cancer | 498 | Article |
3 | Biopharmaceutical benchmarks 2014 | 2014 | Nature Biotechnology | 275 | Article |
4 | A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study | 2013 | Annals of the Rheumatic Diseases | 269 | Article |
5 | A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study | 2013 | Annals of the Rheumatic Diseases | 250 | Article |
6 | Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars | 2012 | Nature Reviews Drug Discovery | 215 | Review |
7 | PEG-modified biopharmaceuticals | 2009 | Expert Opinion on Drug Delivery | 201 | Review |
8 | The challenge of biosimilars | 2008 | Annals of Oncology | 178 | Review |
9 | Sublingual immunotherapy: World Allergy Organization position paper 2013 update | 2014 | World Allergy Organization Journal | 172 | Review |
10 | Biosimilars: What clinicians should know | 2012 | Blood | 158 | Review |